Home  |   Equities  |   Indexes  |   Commodities  |   Forex  |   News  |   Analysis  |   Top/Flop  |   Screening  |   Forums
May 25, 2012 02:09 pm US/Eastern
Member access

4-Traders Homepage  >  Shares  >  Madrid (SIBE)  >  Almirall SA    ALM   ES0157097017

Real time Streaming quotes -

ALMIRALL SA

 (ALM)

 
End-of-day quote. End-of-day quote Madrid (SIBE) - 05/25
5.92 EUR   +5.71%
03/29 ALMIRALL SA: Almirall y Forest Laboratories anuncian que la FDA ha extendi..
03/27 ALMIRALL SA: Almirall y Menarini firman un acuerdo de licencia y alianza c..
03/22 ALMIRALL SA: El estudio ATTAIN con aclidinio publicado en la European Resp..
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
 

Almirall SA : Almirall celebrates 10 years in Mexico

02/02/2012 | 07:18am

Barcelona, 2 February 2012.-  Almirall, an international research-based company committed to health, is celebrating its ten anniversary in Mexico. 

Over the last three years Almirall Mexicohas launched nine products to treat diseases such as irritable bowel syndrome, gastroesophageal reflux and dyspepsia, among others, along with a dermatology line to treat skin disorders.

Almirall Mexicowas also recently awarded the distinguished award Company with Transparent Practices for its ethical responsibility. 

Israel García, General Manager in Mexico, stated:  "the success of our launches has enabled us to consolidate ourselves in Mexicothrough 10 years of continuous growth. Our goal is to keep offering therapeutic solutions of high added value to the Mexican society".

To celebrate this anniversary the pharmaceutical company held a commemorative event at the Museumof Economyin Mexico, D.F., which was attended by the Almirall Mexico team and other company members, as well as dignitaries from the industry and healthcare sector. 

Its commitment to innovation and internationalisation has enabled Almirall to expand worldwide. Almirall now has 12 affiliates in Europeand Latin America, and its proprietary research medicines are present in 70 countries in the five continents.  

About Almirall
Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing.    

Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), gastrointestinal disorders, psoriasis and other dermatological conditions. 

Almirall's products are currently present in over 70 countries while it has direct presence in Europeand Latin Americathrough 12 affiliates. 

For further information please visit the website at: www.almirall.com

More information: 

Ketchum Pleon:
Sonia San Segundo
Tel. +34 91 788 32 00
sonia.sansegundo@ketchumpleon.com

 
React to this article
Latest news on ALMIRALL SA
03/29 Almirall y Forest Laboratories anuncian que la FDA ha extendido el período de re..
03/27 Almirall y Menarini firman un acuerdo de licencia y alianza comercial para aclid..
03/22 El estudio ATTAIN con aclidinio publicado en la European Respiratory Journal con..
03/15 El tratamiento personalizado de la EPOC, principal reto para los especialistas
03/15 Almirall amplía los derechos de comercialización de Sativex® a México
02/29 Almirall supports European post-graduate clinical research into MS spasticity wi..
02/27 Almirall Results 2011 in line, positive newsflow start to 2012
02/24 Almirall and Forest Announce Positive FDA Advisory Committee’s Recommendation fo..
02/21DJForest Labs Lung Drug Effective For COPD; Raises Concerns
02/13 Almirall licenses Aclidinium to Daewoong in Korea
Advertisement
Chart
Duration : Period :
Almirall SA Technical Analysis Chart | ALM | ES0157097017 | 4-Traders
Income Statement Evolution
Almirall SA : Income Statement Evolution
More Financials
Advertisement